Align Technology, Inc. vs Celestica Inc — how do they compare? Align Technology, Inc. trades at $173.97 (market cap $12.29B), while Celestica Inc trades at $337.04 (market cap $39.16B). The key difference: Celestica Inc is far larger — about 3.2× Align Technology, Inc.'s market cap, and Align Technology, Inc. is trading nearer its 52-week high, Celestica Inc nearer its low. Which is the better fit depends on your goals.
| ALGN | CLS | |
|---|---|---|
Market Cap | $12.29B | $39.16B |
Sector | Health | Technology |
52-Week High | $197.51 | $472.40 |
52-Week Low | $124.88 | $181.34 |
Enterprise Value | $11.30B | $39.44B |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.4, down 1.5% today, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 30.03, and a net income margin of 9.99%. Recent news highlights a patent win in China and strategic initiatives under activist investor engagement, supporting its digital orthodontics leadership.
Outlook remains positive due to solid profitability and growth initiatives, but risks include competitive pressures and scanner segment weakness. Analyst consensus is strongly bullish with 73% buy ratings, viewing current valuation as attractive for long-term growth despite near-term technical headwinds.
CLS trades at $327.15, up 3.99% in 24 hours, with a bearish technical signal but strong fundamentals including a 52.69% ROE and Q2 2026 EPS of $2.54 beating estimates. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, though this may cause near-term dilution.
The outlook is positive with analyst consensus at Buy (64.29%) and a $466.50 price target, driven by AI demand and partnerships. Risks include equity dilution and premium valuation, but growth catalysts from hyperscaler investments support long-term upside.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →